BIOMAT Database Logo BIOMAT Database Logo

Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge. 2015

Falko Schmeisser, and Anupama Vasudevan, and Swati Verma, and Wei Wang, and Esmeralda Alvarado, and Carol Weiss, and Vajini Atukorale, and Clement Meseda, and Jerry P Weir
Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States of America.

Identifying major antigenic and protective epitopes of the H7 hemagglutinin (HA) will be important for understanding the antibody response to vaccines developed against the novel influenza H7N9 viruses that emerged in China in 2013. To facilitate antigenic characterization of the H7N9 HA and to develop reagents for evaluation of H7N9 candidate vaccines, we generated a panel of murine monoclonal antibodies (mAbs) to the HA of A/Shanghai/2/2013 using mammalian cell-derived virus-like particles (VLP) containing the H7 HA. Neutralizing antibodies identified an HA epitope corresponding to antigenic site A on the structurally similar influenza H3 hemagglutinin. Importantly, the neutralizing antibodies protect against A/Shanghai/2/2013 challenge. This antigenic site is conserved among many H7 viruses, including strains of both Eurasian and North American lineage, and the isolated neutralizing antibodies are cross-reactive with older H7 vaccine strains. The results indicate that the identified antigenic site is a potentially important protective epitope and suggest the potential benefit of cross-reactive antibody responses to vaccination with H7 candidate vaccines.

UI MeSH Term Description Entries
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D057134 Antibodies, Neutralizing Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus. Neutralizing Antibodies,Antibody, Neutralizing,Neutralizing Antibody
D019267 Hemagglutinin Glycoproteins, Influenza Virus Membrane glycoproteins from influenza viruses which are involved in hemagglutination, virus attachment, and envelope fusion. Fourteen distinct subtypes of HA glycoproteins and nine of NA glycoproteins have been identified from INFLUENZA A VIRUS; no subtypes have been identified for Influenza B or Influenza C viruses.
D064766 Influenza A Virus, H7N9 Subtype A subtype of INFLUENZA A VIRUS with the surface proteins hemagglutinin 7 and neuraminidase 9. This avian origin virus was first identified in humans in 2013. H7N9 subtype,H7N9 Virus,H7N9 Viruses,H7N9 subtypes,Virus, H7N9,subtype, H7N9

Related Publications

Falko Schmeisser, and Anupama Vasudevan, and Swati Verma, and Wei Wang, and Esmeralda Alvarado, and Carol Weiss, and Vajini Atukorale, and Clement Meseda, and Jerry P Weir
Immune-engineered H7N9 influenza hemagglutinin improves protection against viral influenza virus challenge.
September 2020, Human vaccines & immunotherapeutics,
Falko Schmeisser, and Anupama Vasudevan, and Swati Verma, and Wei Wang, and Esmeralda Alvarado, and Carol Weiss, and Vajini Atukorale, and Clement Meseda, and Jerry P Weir
C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge.
August 2000, Nature immunology,
Falko Schmeisser, and Anupama Vasudevan, and Swati Verma, and Wei Wang, and Esmeralda Alvarado, and Carol Weiss, and Vajini Atukorale, and Clement Meseda, and Jerry P Weir
Antigenic Drift of Influenza A(H7N9) Virus Hemagglutinin.
January 2019, The Journal of infectious diseases,
Falko Schmeisser, and Anupama Vasudevan, and Swati Verma, and Wei Wang, and Esmeralda Alvarado, and Carol Weiss, and Vajini Atukorale, and Clement Meseda, and Jerry P Weir
Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting.
November 2016, Science (New York, N.Y.),
Falko Schmeisser, and Anupama Vasudevan, and Swati Verma, and Wei Wang, and Esmeralda Alvarado, and Carol Weiss, and Vajini Atukorale, and Clement Meseda, and Jerry P Weir
Characterization of A/H7 influenza virus global antigenic diversity and key determinants in the hemagglutinin globular head mediating A/H7N9 antigenic evolution.
October 2023, mBio,
Falko Schmeisser, and Anupama Vasudevan, and Swati Verma, and Wei Wang, and Esmeralda Alvarado, and Carol Weiss, and Vajini Atukorale, and Clement Meseda, and Jerry P Weir
Anti-influenza H7 human antibody targets antigenic site in hemagglutinin head domain interface.
September 2020, The Journal of clinical investigation,
Falko Schmeisser, and Anupama Vasudevan, and Swati Verma, and Wei Wang, and Esmeralda Alvarado, and Carol Weiss, and Vajini Atukorale, and Clement Meseda, and Jerry P Weir
Influenza H7N9 Virus Hemagglutinin with T169A Mutation Possesses Enhanced Thermostability and Provides Effective Immune Protection against Lethal H7N9 Virus Challenge in Chickens.
August 2023, Vaccines,
Falko Schmeisser, and Anupama Vasudevan, and Swati Verma, and Wei Wang, and Esmeralda Alvarado, and Carol Weiss, and Vajini Atukorale, and Clement Meseda, and Jerry P Weir
Divergent H7 immunogens offer protection from H7N9 virus challenge.
April 2014, Journal of virology,
Falko Schmeisser, and Anupama Vasudevan, and Swati Verma, and Wei Wang, and Esmeralda Alvarado, and Carol Weiss, and Vajini Atukorale, and Clement Meseda, and Jerry P Weir
Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus.
September 2015, Vaccine,
Falko Schmeisser, and Anupama Vasudevan, and Swati Verma, and Wei Wang, and Esmeralda Alvarado, and Carol Weiss, and Vajini Atukorale, and Clement Meseda, and Jerry P Weir
[Development and characterization of monoclonal antibodies against H7 hemagglutinin of avian influenza virus].
October 2007, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,
Copied contents to your clipboard!